News Feed

Glenmark Pharmaceuticals Inducted into the Dow Jones Sustainability Indices (DJSI) Emerging Markets 2018, One of the Most Prestigious Global Sustainability Benchmarks

Glenmark is one among the only 10 companies from India to be listed in the DJSI Emerging Markets Index From 94 companies listed in the Emerging Markets Index, only two companies have made it from the Pharmaceuticals, Biotechnology & Life Sciences industry DJSI is one of the world's premier benchmark for sustainable business practices Mumbai, India; September 19, 2018 – Glenmark Pharmaceuticals Ltd. has been listed on the Dow Jones Sustainability Indices 2018. Dow Jones Sustainability Index (DJSI) is one of the most esteemed global benchmarks for sustainable business practices. Only the top ranked companies in terms of Corporate Sustainability within each industry are selected to be featured in the index. The inclusion in this list is considered highly prestigious by global investors, financial analysts and other stakeholders and also serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Speaking on the achievement, Glenn Saldanha, Chairman and Managing Director said, “Glenmark is proud to be included in the Dow Jones Sustainability Emerging Markets Index 2018. Being listed in the index is a landmark achievement for us and it re-emphasizes our efforts towards Environment, Social and Governance factors and how over the years we have emerged as a leader in the area of sustainability. This honour has motivated us to continue working on strengthening our actions to build a sustainable future.” The DJSI Emerging Market leaders were chosen from over 800 companies who were assessed, out of which 94 made it to the Index. A focussed approach on sustainable practices in conducting the core business, operations and social investments has facilitated Glenmark to be among the only 2 pharmaceutical companies to be featured in the Emerging Markets Index. From India there are only 10 companies who have made it to this prestigious listing. The evaluation included 24 long-term economic, environmental and social criteria. Glenmark secured high scores for Marketing Practices, Product Quality and Recall, Environmental Policy and Management System, Corporate Citizenship and Philanthropy, Health Outcome Contribution and Code of Business Conduct. Glenmark’s philosophy is to conduct its operations in a manner that is ethical, transparent, proactive, environmentally conscious and sensitive to all its stakeholders. A strong focus on innovation, good corporate governance, operational excellence, quality, environment practices and social responsibility provides the necessary foundation in the quest to become a leading sustainable organisation. About Dow Jones Sustainability Indices The DJSI is the foremost global benchmark for corporate sustainability. Launched in 1999, the DJSI World represents the gold standard for corporate sustainability and is the first global index to track the leading sustainability-driven companies based on RobecoSAM’s analysis of financially material Environmental, Social, and Governance (ESG) factors and S&P DJI’s robust index methodology. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory. The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India. For further information, please contact: An Phan +1-201-331-4218 Isha Trivedi +91-22-4018-9801 corpcomm@glenmarkpharma.com

Glenmark Pharmaceuticals Inducted into the Dow Jones Sustainability Indices (DJSI) Emerging Markets 2018, One of the Most Prestigious Global Sustainability Benchmarks

Glenmark is one among the only 10 companies from India to be listed in the DJSI Emerging Markets Index From 94 companies listed in the Emerging Markets Index, only two companies have made it from the Pharmaceuticals, Biotechnology & Life Sciences industry DJSI is one of the world's premier benchmark for sustainable business practices Mumbai, India; September 19, 2018 – Glenmark Pharmaceuticals Ltd. has been listed on the Dow Jones Sustainability Indices 2018. Dow Jones Sustainability Index (DJSI) is one of the most esteemed global benchmarks for sustainable business practices. Only the top ranked companies in terms of Corporate Sustainability within each industry are selected to be featured in the index. The inclusion in this list is considered highly prestigious by global investors, financial analysts and other stakeholders and also serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Speaking on the achievement, Glenn Saldanha, Chairman and Managing Director said, “Glenmark is proud to be included in the Dow Jones Sustainability Emerging Markets Index 2018. Being listed in the index is a landmark achievement for us and it re-emphasizes our efforts towards Environment, Social and Governance factors and how over the years we have emerged as a leader in the area of sustainability. This honour has motivated us to continue working on strengthening our actions to build a sustainable future.” The DJSI Emerging Market leaders were chosen from over 800 companies who were assessed, out of which 94 made it to the Index. A focussed approach on sustainable practices in conducting the core business, operations and social investments has facilitated Glenmark to be among the only 2 pharmaceutical companies to be featured in the Emerging Markets Index. From India there are only 10 companies who have made it to this prestigious listing. The evaluation included 24 long-term economic, environmental and social criteria. Glenmark secured high scores for Marketing Practices, Product Quality and Recall, Environmental Policy and Management System, Corporate Citizenship and Philanthropy, Health Outcome Contribution and Code of Business Conduct. Glenmark’s philosophy is to conduct its operations in a manner that is ethical, transparent, proactive, environmentally conscious and sensitive to all its stakeholders. A strong focus on innovation, good corporate governance, operational excellence, quality, environment practices and social responsibility provides the necessary foundation in the quest to become a leading sustainable organisation. About Dow Jones Sustainability Indices The DJSI is the foremost global benchmark for corporate sustainability. Launched in 1999, the DJSI World represents the gold standard for corporate sustainability and is the first global index to track the leading sustainability-driven companies based on RobecoSAM’s analysis of financially material Environmental, Social, and Governance (ESG) factors and S&P DJI’s robust index methodology. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory. The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India. For further information, please contact: An Phan +1-201-331-4218 Isha Trivedi +91-22-4018-9801 corpcomm@glenmarkpharma.com